entertainment -WSS

entertainment

author：knowledge 2025-09-03 07:45:12 - browse：57428

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

leisure time

Wikipedia

WSS

Why health workers in Gaza are injured or die at high rates

How climate

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

IVG is promising — but it won’t replace IVF quite yet

FDA struggles to regulate food additives, sometimes for decades

What we owe ALS patients — and why one company fell short

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Hollywood unions extend contract negotiations for actors

Some top drug companies are starting to take action on climate

Novavax promises a turnaround & Lilly roils the obesity market

IVG is promising — but it won’t replace IVF quite yet

Novavax promises a turnaround & Lilly roils the obesity market

Medicare reduced heart disease by changing how it pays doctors

Bright Health sells Medicare Advantage business to Molina

The Karikó problem: Lessons for funding basic research

New air purifier tech could be key to improving indoor air quality

With Roe v Wade overturned, abortion providers work to adapt

Wikipedia

FDA struggles to regulate food additives, sometimes for decades

The explosion of genetic testing requires a new approach

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

CRISPR base editing slashes cholesterol levels in monkeys

The United States is paying nearly triple for new Covid vaccines

STAT Summit: GSK CEO on pharma giant's new direction

leisure time

Wikipedia

focus

hotspot